News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Spectranetics Corporation First Quarter Revenue up 37% to $23.8 Million, Driven by Strong Vascular Intervention and Lead Management Performance
April 23, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Spectranetics Corporation (Nasdaq:SPNC) today reported financial results for the quarter ended March 31, 2008.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Mergers & acquisitions
SpringWorks Surges on Potential $3.5B Merck KGaA Buyout
April 25, 2025
·
2 min read
·
Tristan Manalac
Earnings
Gilead’s PrEP Launch Full Speed Ahead Despite Macro Pressures on HIV Space
April 25, 2025
·
3 min read
·
Tristan Manalac
Earnings
BMS Reports Mixed Earnings as Growth Portfolio Makes Up for Generic Pressure
April 24, 2025
·
2 min read
·
Dan Samorodnitsky
Earnings
Tariff Uncertainty Reigns Over Q1 Earnings, With Merck Taking $200M Blow So Far
April 24, 2025
·
3 min read
·
Annalee Armstrong
